How Should We Treat HAP/VAP Caused by Carbapenemase-Producing Enterobacteriaceae?

Abstract

Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) represent a common problem in hospital setting worldwide. Infections caused by carbapenem-resistant Enterobacteriaceae (CRE) are an emergent problem due to the lack of therapeutic options available, leading to significant increases in morbidity and mortality. CRE have frequently been reported both in HAP/VAP, but limited data regarding the optimal treatment strategy in this setting are available. This review focuses on the current epidemiology of CRE, with a specific focus on HAP/VAP. Moreover, we will suggest a possible strategy for the empiric and targeted treatment of HAP and VAP in which the involvement of CRE is suspected or is confirmed.

Keywords

hospital-acquired pneumonia - ventilator-acquired pneumonia - carbapenemase-producing Enterobacteriaceae - antibiotic therapy - multidrug-resistant gram negative

• References

• 1 Kalil AC, Metersky ML, Klompas M. , et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis 2016; 63 (05) e61-e111
• 2 Magill SS, Edwards JR, Fridkin SK. ; Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Survey of health care-associated infections. N Engl J Med 2014; 370 (26) 2542-2543
• 3 Barbier F, Andremont A, Wolff M, Bouadma L. Hospital-acquired pneumonia and ventilator-associated pneumonia: recent advances in epidemiology and management. Curr Opin Pulm Med 2013; 19 (03) 216-228
• 4 Bassetti M, Taramasso L, Giacobbe DR, Pelosi P. Management of ventilator-associated pneumonia: epidemiology, diagnosis and antimicrobial therapy. Expert Rev Anti Infect Ther 2012; 10 (05) 585-596
• 5 Zhang X, Wang R, Di X, Liu B, Liu Y. Different microbiological and clinical aspects of lower respiratory tract infections between China and European/American countries. J Thorac Dis 2014; 6 (02) 134-142
• 6 Quartin AA, Scerpella EG, Puttagunta S, Kett DH. A comparison of microbiology and demographics among patients with healthcare-associated, hospital-acquired, and ventilator-associated pneumonia: a retrospective analysis of 1184 patients from a large, international study. BMC Infect Dis 2013; 13: 561
• 7 Herkel T, Uvizl R, Doubravska L. , et al. Epidemiology of hospital-acquired pneumonia: Results of a Central European multicenter, prospective, observational study compared with data from the European region. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2016; 160 (03) 448-455
• 8 Delle Rose D, Pezzotti P, Fortunato E. , et al. Clinical predictors and microbiology of ventilator-associated pneumonia in the intensive care unit: a retrospective analysis in six Italian hospitals. Eur J Clin Microbiol Infect Dis 2016; 35 (09) 1531-1539
• 9 Tumbarello M, Viale P, Viscoli C. , et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55 (07) 943-950
• 10 Pea F, Della Siega P, Cojutti P. , et al. Might real-time pharmacokinetic/pharmacodynamic optimisation of high-dose continuous-infusion meropenem improve clinical cure in infections caused by KPC-producing Klebsiella pneumoniae?. Int J Antimicrob Agents 2017; 49 (02) 255-258
• 11 Centers for Disease Control and Prevention. Facility guidance for control of carbapenem-resistant enterobacteriaceae (CRE)–November 2015 update CRE toolkit. Available at: https://www.cdc.gov/hai/organisms/cre/cre-toolkit/ . Accessed April 14, 2017
• 12 van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2016; 11: 1-10
• 13 The European Committee on Antimicrobial Susceptibility Testing. EUCAST guideline for the detection of resistance mechanisms and specific resistances of clinical and/or epidemiological importance. Available at: http://www.eucast.org/resistance_mechanisms/ . Accessed April 14, 2017
• 14 Center for Disease Dynamics, Economics & Policy. Available at: http://www.cddep.org . Accessed April 14, 2017
• 15 Centers for Diseases Control and Prevention. Available at: https://www.cdc.gov/drugresistance/pdf/ar-threats-2013-508.pdf . Accessed April 14, 2017
• 16 Albiger B, Glasner C, Struelens MJ, Grundmann H, Monnet DL. ; European Survey of Carbapenemase-Producing Enterobacteriaceae (EuSCAPE) working group. Carbapenemase-producing Enterobacteriaceae in Europe: assessment by national experts from 38 countries, May 2015. Euro Surveill 2015; 20 (45) 1-6
• 17 The European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe Annual report of the European Antimicrobial Resistance Surveillance Network (EARS-Net) 2014. Available at: http://ecdc.europa.eu/en/publications/publications/antimicrobial-resistance-europe-2014.pdf
• 18 Jeannot K, Bolard A, Plésiat P. Resistance to polymyxins in Gram-negative organisms. Int J Antimicrob Agents 2017; S0924-8579(17)30032-8
• 19 Capone A, Giannella M, Fortini D. , et al; SEERBIO-GRAB network. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin Microbiol Infect 2013; 19 (01) E23-E30
• 20 Giacobbe DR, Del Bono V, Trecarichi EM. , et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Risk factors for bloodstream infections due to colistin-resistant KPC-producing Klebsiella pneumoniae: results from a multicenter case-control-control study. Clin Microbiol Infect 2015; 21 (12) 1106.e1-1106.e8
• 21 de Maio Carrilho CM, de Oliveira LM, Gaudereto J. , et al. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome. BMC Infect Dis 2016; 16 (01) 629
• 22 Wang Q, Zhang Y, Yao X. , et al. Risk factors and clinical outcomes for carbapenem-resistant Enterobacteriaceae nosocomial infections. Eur J Clin Microbiol Infect Dis 2016; 35 (10) 1679-1689
• 23 Qureshi ZA, Paterson DL, Potoski BA. , et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56 (04) 2108-2113
• 24 European Centre for Disease Prevention and Control. Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. Stockholm: ECDC; 2011. Available at: http://ecdc.europa.eu/en/publications/Publications/110913_Risk_assessment_resistant_CPE.pdf . Assessed April 14, 2017
• 25 Tuon FF, Rocha JL, Toledo P. , et al. Risk factors for KPC-producing Klebsiella pneumoniae bacteremia. Braz J Infect Dis 2012; 16 (05) 416-419
• 26 da Silva KE, Maciel WG, Sacchi FP. , et al. Risk factors for KPC-producing Klebsiella pneumoniae: watch out for surgery. J Med Microbiol 2016; 65 (06) 547-553
• 27 Mouloudi E, Protonotariou E, Zagorianou A. , et al. Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes. Infect Control Hosp Epidemiol 2010; 31 (12) 1250-1256
• 28 Tumbarello M, Trecarichi EM, Tumietto F. , et al. Predictive models for identification of hospitalized patients harboring KPC-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2014; 58 (06) 3514-3520
• 29 Patel G, Huprikar S, Factor SH, Jenkins SG, Calfee DP. Outcomes of carbapenem-resistant Klebsiella pneumoniae infection and the impact of antimicrobial and adjunctive therapies. Infect Control Hosp Epidemiol 2008; 29 (12) 1099-1106
• 30 Hussein K, Sprecher H, Mashiach T, Oren I, Kassis I, Finkelstein R. Carbapenem resistance among Klebsiella pneumoniae isolates: risk factors, molecular characteristics, and susceptibility patterns. Infect Control Hosp Epidemiol 2009; 30 (07) 666-671
• 31 Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002; 165 (07) 867-903
• 32 Chastre J. Conference summary: ventilator-associated pneumonia. Respir Care 2005; 50 (07) 975-983
• 33 Bassetti M, Welte T, Wunderink RG. Treatment of Gram-negative pneumonia in the critical care setting: is the beta-lactam antibiotic backbone broken beyond repair?. Crit Care 2016; 20: 19
• 34 Garnacho-Montero J, Corcia-Palomo Y, Amaya-Villar R, Martin-Villen L. How to treat VAP due to MDR pathogens in ICU patients. BMC Infect Dis 2014; 14: 135
• 35 Rosso-Fernández C, Garnacho-Montero J, Antonelli M, Dimopoulos G, Cisneros JM. ; MagicBullet study group Safety and efficacy of colistin versus meropenem in the empirical treatment of ventilator-associated pneumonia as part of a macro-project funded by the Seventh Framework Program of the European Commission studying off-patent antibiotics: study protocol for a randomized controlled trial. Trials 2015; 16: 102
• 36 Tumbarello M, Trecarichi EM, De Rosa FG. , et al; ISGRI-SITA (Italian Study Group on Resistant Infections of the Società Italiana Terapia Antinfettiva). Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother 2015; 70 (07) 2133-2143
• 37 Daikos GL, Tsaousi S, Tzouvelekis LS. , et al. Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother 2014; 58 (04) 2322-2328
• 38 Liapikou A, Torres A. Emerging drugs for nosocomial pneumonia. Expert Opin Emerg Drugs 2016; 21 (03) 331-341
• 39 Wunderink RG. Point: Should inhaled antibiotic therapy be routinely used for the treatment of bacterial lower respiratory tract infections in the ICU setting? Yes. Chest 2017; 151 (04) 737-739
• 40 Viaggi B, Sbrana F, Malacarne P, Tascini C. Ventilator-associated pneumonia caused by colistin-resistant KPC-producing Klebsiella pneumoniae: a case report and literature review. Respir Investig 2015; 53 (03) 124-128
• 41 Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15 (11) e732-e739
• 42 Doi Y, Paterson DL. Carbapenemase-producing Enterobacteriaceae. Semin Respir Crit Care Med 2015; 36 (01) 74-84
• 43 Perez F, El Chakhtoura NG, Papp-Wallace KM, Wilson BM, Bonomo RA. Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy?. Expert Opin Pharmacother 2016; 17 (06) 761-781
• 44 Falagas ME, Lourida P, Poulikakos P, Rafailidis PI, Tansarli GS. Antibiotic treatment of infections due to carbapenem-resistant Enterobacteriaceae: systematic evaluation of the available evidence. Antimicrob Agents Chemother 2014; 58 (02) 654-663
• 45 Lorente L, Lorenzo L, Martín MM, Jiménez A, Mora ML. Meropenem by continuous versus intermittent infusion in ventilator-associated pneumonia due to gram-negative bacilli. Ann Pharmacother 2006; 40 (02) 219-223
• 46 Taccone FS, Cotton F, Roisin S, Vincent JL, Jacobs F. Optimal meropenem concentrations to treat multidrug-resistant Pseudomonas aeruginosa septic shock. Antimicrob Agents Chemother 2012; 56 (04) 2129-2131
• 47 Souli M, Karaiskos I, Masgala A, Galani L, Barmpouti E, Giamarellou H. Double-carbapenem combination as salvage therapy for untreatable infections by KPC-2-producing Klebsiella pneumoniae. Eur J Clin Microbiol Infect Dis 2017
• 48 Oliva A, Scorzolini L, Castaldi D. , et al. Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). J Infect 2017; 74 (01) 103-106
• 49 Cprek JB, Gallagher JC. Ertapenem- containing double-carbapenem therapy for treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae. Antimicrob Agents Chemother 2015; 60 (01) 669-673
• 50 Rizek C, Ferraz JR, van der Heijden IM. , et al. In vitro activity of potential old and new drugs against multidrug-resistant gram-negatives. J Infect Chemother 2015; 21 (02) 114-117
• 51 Kallel H, Hergafi L, Bahloul M. , et al. Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study. Intensive Care Med 2007; 33 (07) 1162-1167
• 52 Imberti R, Cusato M, Villani P. , et al. Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration. Chest 2010; 138 (06) 1333-1339
• 53 Plachouras D, Karvanen M, Friberg LE. , et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria. Antimicrob Agents Chemother 2009; 53 (08) 3430-3436
• 54 Gaibani P, Lombardo D, Lewis RE. , et al. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. J Antimicrob Chemother 2014; 69 (07) 1856-1865
• 55 Freire AT, Melnyk V, Kim MJ. , et al; 311 Study Group. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis 2010; 68 (02) 140-151
• 56 Burkhardt O, Rauch K, Kaever V, Hadem J, Kielstein JT, Welte T. Tigecycline possibly underdosed for the treatment of pneumonia: a pharmacokinetic viewpoint. Int J Antimicrob Agents 2009; 34 (01) 101-102
• 57 Poulakou G, Bassetti M, Righi E, Dimopoulos G. Current and future treatment options for infections caused by multidrug-resistant Gram-negative pathogens. Future Microbiol 2014; 9 (09) 1053-1069
• 58 Bassetti M, De Waele JJ, Eggimann P. , et al. Preventive and therapeutic strategies in critically ill patients with highly resistant bacteria. Intensive Care Med 2015; 41 (05) 776-795
• 59 Panidis D, Markantonis SL, Boutzouka E, Karatzas S, Baltopoulos G. Penetration of gentamicin into the alveolar lining fluid of critically ill patients with ventilator-associated pneumonia. Chest 2005; 128 (02) 545-552
• 60 Buehrle DJ, Shields RK, Clarke LG, Potoski BA, Clancy CJ, Nguyen MH. Carbapenem-Resistant Pseudomonas aeruginosa Bacteremia: Risk Factors for Mortality and Microbiologic Treatment Failure. Antimicrob Agents Chemother 2017
• 61 Pontikis K, Karaiskos I, Bastani S. , et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria. Int J Antimicrob Agents 2014; 43 (01) 52-59
• 62 Vasoo S, Cunningham SA, Cole NC. , et al. In vitro activities of ceftazidime-avibactam, aztreonam-avibactam, and a panel of older and contemporary antimicrobial agents against carbapenemase-producing gram-negative bacilli. Antimicrob Agents Chemother 2015; 59 (12) 7842-7846
• 63 Bassetti M, Righi E, Carnelutti A. New therapeutic options for respiratory tract infections. Curr Opin Infect Dis 2016; 29 (02) 178-186
• 64 Sader HS, Castanheira M, Flamm RK. Antimicrobial activity of ceftazidime-avibactam when tested against gram-negative bacteria isolated from patients hospitalized with pneumonia in United States medical centers (2011-2015). Antimicrob Agents Chemother 2017; AAC.02083-16
• 65 Temkin E, Torre-Cisneros J, Beovic B. , et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother 2017; 61 (02) e01964-e02016
• 66 Shields RK, Potoski BA, Haidar G. , et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant enterobacteriaceae infections. Clin Infect Dis 2016; 63 (12) 1615-1618
• 67 Castanheira M, Rhomberg PR, Flamm RK, Jones RN. Effect of the β- lactamase inhibitor vaborbactam combined with meropenem against serine carbapenemase-producing enterobacteriaceae. Antimicrob Agents Chemother 2016; 60 (09) 5454-5458
• 68 Bassetti M, Luyt CE, Nicolau DP, Pugin J. Characteristics of an ideal nebulized antibiotic for the treatment of pneumonia in the intubated patient. Ann Intensive Care 2016; 6 (01) 35
• 69 Solé-Lleonart C, Rouby JJ, Blot S. , et al. Nebulization of antiinfective agents in invasively mechanically ventilated adults: a systematic review and meta-analysis. Anesthesiology 2017
• 70 Solé-Lleonart C, Roberts JA, Chastre J. , et al; ESGCIP Investigators. Global survey on nebulization of antimicrobial agents in mechanically ventilated patients: a call for international guidelines. Clin Microbiol Infect 2016; 22 (04) 359-364
• 71 Chastre J, Wolff M, Fagon JY. , et al; PneumA Trial Group. Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults: a randomized trial. JAMA 2003; 290 (19) 2588-2598
• 72 Dimopoulos G, Poulakou G, Pneumatikos IA, Armaganidis A, Kollef MH, Matthaiou DK. Short- vs long-duration antibiotic regimens for ventilator-associated pneumonia: a systematic review and meta-analysis. Chest 2013; 144 (06) 1759-1767
• 73 Schuetz P, Raad I, Amin DN. Using procalcitonin-guided algorithms to improve antimicrobial therapy in ICU patients with respiratory infections and sepsis. Curr Opin Crit Care 2013; 19 (05) 453-460
• 74 Stolz D, Smyrnios N, Eggimann P. , et al. Procalcitonin for reduced antibiotic exposure in ventilator-associated pneumonia: a randomised study. Eur Respir J 2009; 34 (06) 1364-1375